Abstract
Background The second-generation drug-eluting stents (DES) have shown superiority in many studies relating to safety and efficacy when compared with the first-generation DES. However, it is unclear whether there are differences in efficacy and safety among the second-generation DES after long-term follow-up. Methods This multicenter, prospective, randomized, open-labeled trial will directly compare the efficacy and safety among the patients treated with either everolimus-eluting stent (EES), zotarolimus-eluting stent with biolinx polymer (ZES-R), or biolimus-eluting stent (BES) with minimal exclusion criteria. The primary end point is a patient-oriented composite consisted of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically indicated target lesion revascularization at 24-month clinical follow-up post-index procedure. With the hypothesis that "BES is non-inferior to EES" or "BES is non-inferior to ZES-R" in primary end point, approximately 2,600 patients will be assigned to one of the types of stents using a web-based randomization system. Conclusions The CHOICE trial will directly compare the efficacy and safety of EES, ZES-R, and BES in everyday clinical practice for long-term follow-up.
Original language | English |
---|---|
Pages (from-to) | 224-229 |
Number of pages | 6 |
Journal | American Heart Journal |
Volume | 166 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2013 Aug |
Externally published | Yes |
Bibliographical note
Funding Information:This study is supported by Gangwon Cardiovascular Health Research Institute, Wonju, Korea. Gangwon Cardiovascular Health Research Institute was not involved in study design, data collection, data analysis, and writing of the report. The authors are solely responsible for the design and conduct of this study, all study analyses, and the drafting and editing of the manuscript.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine